These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22087278)

  • 21. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.
    Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S
    Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents.
    Luo J; Swaminath G; Brown SP; Zhang J; Guo Q; Chen M; Nguyen K; Tran T; Miao L; Dransfield PJ; Vimolratana M; Houze JB; Wong S; Toteva M; Shan B; Li F; Zhuang R; Lin DC
    PLoS One; 2012; 7(10):e46300. PubMed ID: 23056280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents.
    Fjellström O; Larsson N; Yasuda S; Tsuchida T; Oguma T; Marley A; Wennberg-Huldt C; Hovdal D; Fukuda H; Yoneyama Y; Sasaki K; Johansson A; Lundqvist S; Brengdahl J; Isaacs RJ; Brown D; Geschwindner S; Benthem L; Priest C; Turnbull A
    PLoS One; 2015; 10(12):e0145849. PubMed ID: 26720709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GPR40-Mediated G
    Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
    Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets.
    Alquier T; Peyot ML; Latour MG; Kebede M; Sorensen CM; Gesta S; Ronald Kahn C; Smith RD; Jetton TL; Metz TO; Prentki M; Poitout V
    Diabetes; 2009 Nov; 58(11):2607-15. PubMed ID: 19720802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent.
    Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Cheewatrakoolpong B; Xue J; Szeto D; Forrest G; Miller C; Bunzel M; Plummer CW; Chobanian HR; Miller MW; Souza S; Thomas-Fowlkes BS; Ogawa AM; Weinglass AB; Di Salvo J; Li X; Feng Y; Tatosian DA; Howard AD; Colletti SL; Trujillo ME
    PLoS One; 2017; 12(10):e0186033. PubMed ID: 29053717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasiglifam/TAK-875, a Selective GPR40 Agonist, Improves Hyperglycemia in Rats Unresponsive to Sulfonylureas and Acts Additively with Sulfonylureas.
    Ito R; Tsujihata Y; Suzuki M; Miyawaki K; Matsuda K; Takeuchi K
    J Pharmacol Exp Ther; 2016 Apr; 357(1):217-27. PubMed ID: 26813930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linoleic acid activates GPR40/FFA1 and phospholipase C to increase [Ca2+]i release and insulin secretion in islet beta-cells.
    Zhou YJ; Song YL; Zhou H; Li Y
    Chin Med Sci J; 2012 Mar; 27(1):18-23. PubMed ID: 22734209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GPR40 full agonism exerts feeding suppression and weight loss through afferent vagal nerve.
    Ueno H; Ito R; Abe SI; Ogino H; Maruyama M; Miyashita H; Miyamoto Y; Moritoh Y; Tsujihata Y; Takeuchi K; Nishigaki N
    PLoS One; 2019; 14(9):e0222653. PubMed ID: 31525244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Flatt PR
    Br J Pharmacol; 2013 Nov; 170(5):978-90. PubMed ID: 23992544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
    Mohammad S
    Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice.
    Nagasumi K; Esaki R; Iwachidow K; Yasuhara Y; Ogi K; Tanaka H; Nakata M; Yano T; Shimakawa K; Taketomi S; Takeuchi K; Odaka H; Kaisho Y
    Diabetes; 2009 May; 58(5):1067-76. PubMed ID: 19401434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
    Burant CF
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DC260126, a small-molecule antagonist of GPR40, improves insulin tolerance but not glucose tolerance in obese Zucker rats.
    Zhang X; Yan G; Li Y; Zhu W; Wang H
    Biomed Pharmacother; 2010 Nov; 64(9):647-51. PubMed ID: 20888730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes.
    Araki T; Hirayama M; Hiroi S; Kaku K
    Diabetes Obes Metab; 2012 Mar; 14(3):271-8. PubMed ID: 22051148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.